BR112022021039A2 - Ensaio de anticorpo neutralizante para proteínas terapêuticas - Google Patents

Ensaio de anticorpo neutralizante para proteínas terapêuticas

Info

Publication number
BR112022021039A2
BR112022021039A2 BR112022021039A BR112022021039A BR112022021039A2 BR 112022021039 A2 BR112022021039 A2 BR 112022021039A2 BR 112022021039 A BR112022021039 A BR 112022021039A BR 112022021039 A BR112022021039 A BR 112022021039A BR 112022021039 A2 BR112022021039 A2 BR 112022021039A2
Authority
BR
Brazil
Prior art keywords
therapeutic proteins
neutralizing antibody
antibody assay
relates
present
Prior art date
Application number
BR112022021039A
Other languages
English (en)
Inventor
Partridge Michael
Irvin Susan
Rajadhyaksha Manoj
HERMANN Aynur
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112022021039A2 publication Critical patent/BR112022021039A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

ENSAIO DE ANTICORPO NEUTRALIZANTE PARA PROTEÍNAS TERAPÊUTICAS. A presente invenção refere-se a métodos de teste para a presença de anticorpos neutralizantes (NAbs) contra proteínas terapêuticas. Em particular, a presente invenção refere-se ao uso de agentes atenuantes contra fármacos concorrentes interferentes em ensaios de ligação ao ligante ou ensaios baseados em células para a detecção de anticorpos neutralizantes contra proteínas terapêuticas.
BR112022021039A 2020-05-01 2021-04-30 Ensaio de anticorpo neutralizante para proteínas terapêuticas BR112022021039A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063018821P 2020-05-01 2020-05-01
US202063041768P 2020-06-19 2020-06-19
US202163172488P 2021-04-08 2021-04-08
PCT/US2021/030099 WO2021222711A1 (en) 2020-05-01 2021-04-30 Neutralizing antibody assay for therapeutic proteins

Publications (1)

Publication Number Publication Date
BR112022021039A2 true BR112022021039A2 (pt) 2022-12-06

Family

ID=76012048

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021039A BR112022021039A2 (pt) 2020-05-01 2021-04-30 Ensaio de anticorpo neutralizante para proteínas terapêuticas

Country Status (11)

Country Link
US (2) US20210341487A1 (pt)
EP (1) EP4143573A1 (pt)
JP (1) JP2023524062A (pt)
KR (1) KR20230005936A (pt)
CN (1) CN115867808A (pt)
AU (1) AU2021263487A1 (pt)
BR (1) BR112022021039A2 (pt)
CA (1) CA3180569A1 (pt)
IL (1) IL297783A (pt)
MX (1) MX2022013738A (pt)
WO (1) WO2021222711A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023214960A1 (en) * 2022-05-02 2023-11-09 Regeneron Pharmaceuticals, Inc. Biochemical assays for therapeutic proteins
WO2024064044A1 (en) * 2022-09-23 2024-03-28 Merck Sharp & Dohme Llc Neutralization antibody assay method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1902320B1 (en) * 2005-05-20 2010-03-10 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
MX2016005686A (es) * 2013-10-31 2016-08-11 Regeneron Pharma Ensayo de union competitiva al ligando para detectar anticuerpos neutralizantes.
RS58212B1 (sr) * 2014-02-11 2019-03-29 Genzyme Corp Testovi za otkrivanje prisustva ili količine anti-lek antitela
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
WO2017024465A1 (en) * 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
US9995753B2 (en) * 2015-09-25 2018-06-12 Merck Sharp & Dohme Corp. Anti-pembrolizumab antibodies
CN112534263A (zh) * 2018-08-03 2021-03-19 百时美施贵宝公司 用于检测抗药抗体的方法

Also Published As

Publication number Publication date
MX2022013738A (es) 2022-11-16
JP2023524062A (ja) 2023-06-08
AU2021263487A1 (en) 2022-11-17
EP4143573A1 (en) 2023-03-08
KR20230005936A (ko) 2023-01-10
US20210341487A1 (en) 2021-11-04
CA3180569A1 (en) 2021-11-04
IL297783A (en) 2022-12-01
CN115867808A (zh) 2023-03-28
WO2021222711A1 (en) 2021-11-04
US20220260577A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
BR112022021039A2 (pt) Ensaio de anticorpo neutralizante para proteínas terapêuticas
MX2009004460A (es) Inmunoensayo de analitos en muestras que contienen anticuerpos anti-analito endogenos.
Li et al. A gold nanoparticle-based lateral flow immunosensor for ultrasensitive detection of tetrodotoxin
ATE438853T1 (de) Diagnostische testvorrichtung
MX2007014815A (es) Metodos de inmunoanalisis mejorados.
BRPI0707645B8 (pt) métodos in vitro para detecção de câncer em um indivíduo e para avaliação de prognóstico de um indivíduo tendo, ou suspeito de ter, câncer ovariano
BR112018005812A2 (pt) ?método de imunoensaio para a detecção de um analito, kit de reagentes para detectar um analito por um imunoensaio e uso de um parceiro de ligação marcador-específico?
Yakes et al. First report of a direct surface plasmon resonance immunosensor for a small molecule seafood toxin
TW200741203A (en) Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
BRPI0915086B8 (pt) detecção do uso de canabis
Boscolo et al. Sandwich ELISA assay for the quantitation of palytoxin and its analogs in natural samples
ATE408837T1 (de) Verfahren zum nachweis von infektionen mit mykobakterien
Lakshmipriya et al. Signal enhancement in ELISA: Biotin-streptavidin technology against gold nanoparticles
BR112012029769A2 (pt) processo para a detecção eletroquímica de reações de ligação
BRPI0519354A2 (pt) mÉtodo para detecÇço de um anticorpo terapÊutico e uso de um anticorpo
MY193489A (en) Immunochromatography test piece for extracting and measuring sugar chain antigen, which is capable of preventing non-specific reaction
CN104487590A (zh) 酶检测装置
WO2023284686A1 (zh) 一种结合抗体的生物传感检测方法及检测系统
MX2022011336A (es) Atenuacion de la interferencia de dianas en ensayo de anticuerpos antifarmacos.
Zhao et al. AlphaLISA for detection of staphylococcal enterotoxin B free from interference by protein A
Welch et al. A chemiluminescent sandwich ELISA enhancement method using a chromium (III) coordination complex
EA201370030A1 (ru) Бифункциональный количественный анализ in vitro связывания мишени для обнаружения нейтрализующих антител к антителам-мишеням
ES2796479T3 (es) Procedimiento de pretratamiento para la detección rápida del antígeno central del VHC
RU2008130888A (ru) Мас-2вр как маркер для диагностики рака желудка
Abdool et al. Circulating CD33 and its clinical value in acute leukemia